Nidanilimab (CAN04) is a fully humanized anti-IL1RAP monoclonal antibody with high affinity (Kd 1.10 pM). It blocks IL-1α/β signaling to exert antitumor effects and is utilized in research for solid tumors like NSCLC and PDAC, with studies demonstrating activity in both in vitro and in vivo models.